Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation.
Evaluation of atherosclerosis is important in the treatment of hypertension. To evaluate the preventive effects of a small amount of alpha-blockade, arterial and endothelial dysfunction were measured by noninvasive tests, i.e., pulse wave velocity, acceleration plethysmography and strain-gauge plethysmography, in patients with essential hypertension. Fifteen patients (65+/-3 years old) with essential hypertension (WHO stage I or II) were analyzed in this study. We performed noninvasive evaluations to measure aortic stiffness and endothelial dysfunction, in addition to measuring blood pressure, cholesterol profile, and levels of cells adhesion molecules and nitric oxide before and 6 and 12 months after the start of doxazosin treatment (1.0 mg/day). Blood pressure and heart rate did not significantly change during treatment. The pulse wave velocity index was significantly reduced both at 6 (7.72+/-0.23 m/s; p<0.05) and 12 (7.34+/-0.26 m/s; p<0.05) months after the start of treatment compared to the pretreatment level that at baseline. There was also a significant improvement in b/a after 12 months (-0.46+/-0.04; p<0.05) and in d/a after 6 months (-0.38+/-0.03; p<0.05) and 12 months (-0.39+/-0.03; p=0.05) compared to the pretreatment values. Moreover, reactive hyperemia evaluated by strain-gauge plethysmography after 6 months (1.34+/-0.11; p<0.05) and 12 months (1.49+/-0.16; p<0.05) was significantly improved compared to that before treatment, and NOx was significantly increased after 12 months (89.7+/-15.7 micromol/l; p<0.005). These data suggest that a low dose of doxazosin may play an important role in improving arterial stiffness and endothelial dysfunction without changing cardiac hemodynamics.
Komai
Norio
N
Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan.
Ohishi
Mitsuru
M
Moriguchi
Atsushi
A
Yanagitani
Yoshihiro
Y
Jinno
Toyohisa
T
Matsumoto
Keiko
K
Katsuya
Tomohiro
T
Rakugi
Hiromi
H
Higaki
Jitsuo
J
Ogihara
Toshio
T
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D001011:Aorta / Q000187:drug effects* / Q000503:physiopathology*; D001161:Arteriosclerosis / Q000175:diagnosis / Q000517:prevention & control*; D017292:Doxazosin / Q000008:administration & dosage* / Q000627:therapeutic use; D004548:Elasticity; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D006940:Hyperemia / Q000209:etiology / Q000503:physiopathology; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D010991:Plethysmography; D011674:Pulse
D000317:Adrenergic alpha-Antagonists; D009566:Nitrates; D009573:Nitrites; D017292:Doxazosin